Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.
Current stock price: 17.85 pence, down 8.5% in London on Monday
12-month change: down 42%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.


(Alliance News) - Angle PLC - Guildford, England-based liquid biopsy company, which is to be renamed CelLBxHealth PLC - Appoints Peter Collins as inte...


(Alliance News) - Angle PLC shares fell on Wednesday, after it announced plans to rename itself CelLBxHealth PLC and "[pursue] a revised strategy", wi...


Angle PLC - Guildford, England-based liquid biopsy company - Says that, following talks with an unnamed "significant shareholder", Chief Executive Off...


Technology investment company ANGLE has raised £1.2m through a fundraising on the same that it revealed it had swung to a loss in the first half ended...


Angle's 90%-owned portfolio company, Parsortix, which specialises in medical diagnostics, has used its cell separation device to successfully capture ...


Angle, the technology investment company, saw its share price go vertical on Friday morning on the back of success at one its investments, Parsortix. ...


Shares in Angle, the Surrey-based technology investment firm, fell today after it reported delays to its IVF product EmbryoSure. The embryo viability...


Angle, the Surrey-based technology investment firm, has seen its share price rocket nearly 15% on news one of its divisions has found a new way to det...


Angle has increased its stake in its subsidiary, Parsotix, to 90% following the success of the cancer diagnostic firm's cell separation device. The ...


Technology firm Angle has announced that Parsortix, its 85% owned portfolio company which specialises in medical diagnostics, has achieved a major mil...


Technology firm incubator Angle saw an acute increase in its share price after one of its subsidiaries was granted a US patent. Angle's 83% owned med...